We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Oral Anticoagulation
MedXY News
EnglishTag

Oral Anticoagulation

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Abelacimab in Atrial Fibrillation: Impact of Prior Anticoagulation Experience on Bleeding Risk
Cardiologybleeding riskOral Anticoagulation

Abelacimab in Atrial Fibrillation: Impact of Prior Anticoagulation Experience on Bleeding Risk

By MedXY|Aug 11, 2026

The AZALEA-TIMI 71 study demonstrates that factor XI inhibition with abelacimab reduces bleeding risk in atrial fibrillation patients regardless of prior oral anticoagulation experience, with a potentially greater absolute benefit in antico

Pre-Treatment Fibrin Clot Lysis Time Predicts Bleeding Risk in Atrial Fibrillation Patients on Oral Anticoagulants
Cardiologyatrial fibrillationbleeding risk

Pre-Treatment Fibrin Clot Lysis Time Predicts Bleeding Risk in Atrial Fibrillation Patients on Oral Anticoagulants

By MedXY|Apr 28, 2026

Shorter pre-treatment fibrin clot lysis time independently predicts higher bleeding risk in AF patients on oral anticoagulation, as evidenced by the ARISTOTLE trial.

Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit
CardiologyExtended TherapyOral Anticoagulation

Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit

By MedXY|Nov 22, 2025

A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit tha

NOAC Monotherapy After Drug‑Eluting Stent: Safer and at Least as Effective as NOAC Plus Clopidogrel in AF Patients ≥1 Year After PCI
Cardiologyatrial fibrillationOral Anticoagulation

NOAC Monotherapy After Drug‑Eluting Stent: Safer and at Least as Effective as NOAC Plus Clopidogrel in AF Patients ≥1 Year After PCI

By MedXY|Nov 10, 2025

In the ADAPT AF‑DES randomized trial, NOAC monotherapy in AF patients with drug‑eluting stents implanted ≥1 year earlier reduced bleeding and was noninferior—and numerically superior—for a composite of ischemic and bleeding outcomes versus

Aspirin Use in Chronic Coronary Syndrome Patients on Oral Anticoagulation: Balancing Risks and Benefits
CardiologyAspirincardiovascular risk

Aspirin Use in Chronic Coronary Syndrome Patients on Oral Anticoagulation: Balancing Risks and Benefits

By MedXY|Oct 31, 2025

A randomized trial revealed that adding aspirin to oral anticoagulation in chronic coronary syndrome patients increases adverse cardiovascular events, mortality, and major bleeding, challenging conventional dual therapy approaches.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities